GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Ligand Pharmaceuticals
Ligand Pharmaceuticals owns a platform that helps other companies develop drugs. Its share price is based not on its own drugs, but on royalties and payments based on the success of its numerous partners' developments, which diversifies risk.
Share prices of companies in the market segment - Pharma other
Ligand Pharmaceuticals owns technology platforms that it licenses to other pharmaceutical companies for drug development. We classify it as part of the other pharmaceuticals sector, and the chart below shows the overall dynamics of this niche, where value depends on the success of its partners.
Broad Market Index - GURU.Markets
Ligand Pharmaceuticals is a biopharmaceutical company with a unique business model: it owns a portfolio of technologies that it licenses to other companies for drug development. As a component of the GURU.Markets index, it receives royalties from its partners' successes. The chart below represents the entire market. See how Ligand shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
LGND - Daily change in the company's share price Ligand Pharmaceuticals
The daily price change of Ligand Pharmaceuticals, a biopharmaceutical platform company, is a measure of its sensitivity to the performance of its partners. Change_co reflects volatility associated with news about drugs developed using its technology. This metric is important for analyzing companies with a royalty model in biotech on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma other
Ligand Pharmaceuticals Incorporated is a biotech company with a unique business model. This chart highlights the sector's high volatility. Comparing it to LGND, which receives royalties from technologies licensed to other pharmaceutical companies, helps us understand it as a diversified bet on the industry.
Daily change in the price of a broad market stock, index - GURU.Markets
Ligand Pharmaceuticals is a biopharmaceutical company with a unique business model based on the development and licensing of technology platforms for drug discovery. The chart below illustrates the volatility of the biotech sector, which is interesting to compare with Ligand's unique story.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Ligand Pharmaceuticals
Ligand is a unique biotech company with a business model based on royalties from its technology platforms. Its annual growth reflects the success of its partners in drug development, making it a diversified biotech bet.
Annual dynamics of market capitalization of the market segment - Pharma other
Ligand Pharmaceuticals Incorporated has a unique business model: it doesn't sell drugs itself, but rather owns technology platforms that it licenses to other pharmaceutical companies in exchange for royalties. The chart below shows how this low-risk, yet highly profitable, model impacts its performance compared to traditional biotech companies.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ligand Pharmaceuticals has a unique business model based on royalties from drugs developed by its partners. This mitigates risk. Its stock price is not dependent on economic cycles, but is driven by the success of its entire drug portfolio, making it more diversified and stable than traditional biotech companies.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Ligand Pharmaceuticals
Ligand Pharmaceuticals doesn't develop drugs itself, but rather owns platform technologies that it licenses to other pharmaceutical companies. The monthly fluctuations on the chart reflect the royalties it receives from sales of drugs developed using its technologies.
Monthly dynamics of market capitalization of the market segment - Pharma other
Ligand Pharmaceuticals is a biotech company with a unique business model. It owns a technology platform that it licenses to other pharmaceutical companies for drug development, receiving royalties. The chart below illustrates the dynamics of the biotech sector, but Ligand's model offers a more diversified approach.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ligand Pharmaceuticals owns a drug development platform that it licenses to other pharmaceutical companies in exchange for royalties. Its business model is diversified. The chart below illustrates general market trends against which Ligand may exhibit its own unique, less volatile performance.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Ligand Pharmaceuticals
Ligand Pharmaceuticals owns a drug development platform that it licenses to other pharmaceutical companies in exchange for royalties. Its weekly stock price reflects news of its partners' clinical trial successes or failures, making it a diversified biotech bet.
Weekly dynamics of market capitalization of the market segment - Pharma other
Biotech companies with technology platforms like Ligand offer a diversified way to invest in the industry. Their success depends on the success of their partners. The chart below shows the overall dynamics of this segment, allowing one to assess how broad and promising Ligand's partner network is compared to other similar companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Ligand Pharmaceuticals owns a portfolio of proprietary technologies that it licenses to other pharmaceutical companies. Its business model is based on royalties from others' successes. The chart shows how news from its many partners impacts its stock, creating a diversified, yet still biotech, profile.
Market capitalization of the company, segment and market as a whole
LGND - Market capitalization of the company Ligand Pharmaceuticals
Ligand Pharmaceuticals' market capitalization chart reflects investors' assessment of its unique business model, based on technology platforms. Its performance reflects not its own drugs, but the success of its partners who use Ligand's technologies (such as Captisol) to develop their own drugs. The scale of its royalty portfolio reflects the value of its innovations.
LGND - Share of the company's market capitalization Ligand Pharmaceuticals within the market segment - Pharma other
Ligand Pharmaceuticals operates under a unique business model, owning a technology platform that it licenses to other pharmaceutical companies for drug development. Its market share reflects the value of its portfolio of royalties from dozens of approved and currently under development drugs.
Market capitalization of the market segment - Pharma other
Below is a graph reflecting the combined weight of the entire pharmaceutical sector. For Ligand Pharmaceuticals, with its unique business model based on owning technology platforms and receiving royalties, this line represents an ocean of opportunity. The rising graph signifies that the entire industry is actively developing new drugs, many of which utilize Ligand's technologies.
Market capitalization of all companies included in a broad market index - GURU.Markets
Ligand Pharmaceuticals owns a drug development platform that it licenses to other pharmaceutical companies. Its market capitalization is the valuation of its business model, which relies on royalties from other companies' successes. This represents the market share of intellectual property businesses in the pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
LGND - Book value capitalization of the company Ligand Pharmaceuticals
Ligand Pharmaceuticals owns a drug development platform that it licenses to other companies. Its book value is its financial capital and a portfolio of royalties from dozens of approved drugs. This is its "golden" intellectual property portfolio. How has the value of these future cash flows grown? The chart below shows.
LGND - Share of the company's book capitalization Ligand Pharmaceuticals within the market segment - Pharma other
Ligand Pharmaceuticals owns technological platforms rather than manufacturing plants, which are also valuable assets. Its balance sheet reflects the value of technologies, such as Captisol, used by other companies for drug development. The chart shows the share of its unique R&D platforms in the biotech sector's total assets.
Market segment balance sheet capitalization - Pharma other
Ligand Pharmaceuticals has a unique "asset-light" model. Pharmaceuticals, as the chart shows, are capital-intensive. Ligand doesn't sell drugs, but rather owns patents for technologies (the Captisol platform), which it licenses to other companies, receiving royalties.
Book value of all companies included in the broad market index - GURU.Markets
Ligand Pharmaceuticals owns a drug development platform that is used by the entire industry. Its book value is derived from its portfolio of dozens of royalty-generating technologies, as well as its laboratories and capital. The chart shows the material weight of this innovative company, whose "genetic code" is embedded in many successful drugs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Ligand Pharmaceuticals
Ligand Pharmaceuticals doesn't sell drugs, but rather provides the technology to create them. The chart shows the premium the market pays for its diversified royalty portfolio. Investors value its business model, which allows it to profit from the successes of dozens of other pharmaceutical companies.
Market to book capitalization ratio in a market segment - Pharma other
Ligand Pharmaceuticals owns a drug development platform that it licenses to other pharmaceutical companies in exchange for royalties. Its business model is asset-light. The chart shows how the market values its diversified portfolio of future royalties.
Market to book capitalization ratio for the market as a whole
Ligand Pharmaceuticals owns a technology platform that helps other pharmaceutical companies develop new drugs. It doesn't sell the finished products, but receives royalties from their sales. This chart shows the overall market valuation, but how do investors evaluate the "intellectual property" business model in the pharmaceutical industry?
Debts of the company, segment and market as a whole
LGND - Company debts Ligand Pharmaceuticals
Ligand Pharmaceuticals has a unique business model based on royalties from the use of its technologies. This creates a stable cash flow, allowing it to strategically use debt capital to acquire new technologies or rights to future royalties, effectively reinvesting current revenues.
Market segment debts - Pharma other
Ligand Pharmaceuticals has a unique business model: it owns a portfolio of technologies and patents that it licenses to other pharmaceutical companies, receiving royalties. This is less risky than developing drugs independently. This chart shows how its conservative financial structure differs from typical biotech companies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Ligand Pharmaceuticals
Ligand Pharmaceuticals has a business model based on developing and acquiring technologies that are then licensed to other pharmaceutical companies. This chart shows its financial structure. This model is less risky and capital-intensive than full-fledged drug development, often allowing the company to maintain lower debt levels.
Market segment debt to market segment book capitalization - Pharma other
Ligand Pharmaceuticals' model of developing drugs through partnerships and licensing is less risky than pursuing full-scale development. This chart illustrates how the biotech sector generally finances its activities. It allows one to appreciate how Ligand's royalty-based financial structure differs from that of traditional R&D companies.
Debt to book value of all companies in the market
This chart reflects the average "credit appetite" of the entire economy. Ligand Pharmaceuticals has a unique business model based on royalties from other companies' developments. A comparison with the overall market shows how its "lightweight" and less risky financial structure differs from traditional biotech companies and the stock market average.
P/E of the company, segment and market as a whole
P/E - Ligand Pharmaceuticals
This chart for Ligand Pharmaceuticals, a biopharmaceutical company with a platform technology, shows the valuation of its business model. The multiple reflects not so much the success of a single drug but rather the potential of its technologies, which are licensed to dozens of other companies, creating a diversified royalty stream from future drugs.
P/E of the market segment - Pharma other
Ligand's royalty-based drug development is a unique business model. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Ligand is valued not as a traditional biotech company, but as a diversified portfolio of bets on the success of its partners' drugs.
P/E of the market as a whole
Ligand Pharmaceuticals is a biopharmaceutical company with a unique business model: it owns a portfolio of proprietary technologies that it licenses to other companies for drug development, earning royalties. This chart reflects the overall sentiment in the biotech sector. It helps us understand whether Ligand is perceived as a diversified and less risky biotech bet or whether its valuation is moving with the market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Ligand Pharmaceuticals
Ligand Pharmaceuticals is a biopharmaceutical company with a business model based on developing or acquiring technologies that are then licensed to other companies in exchange for royalties. This chart reflects analysts' expectations for the success of its partnership programs. Future revenue depends on the success of drugs developed using Ligand's technologies.
%20P%2FE%20Ligand%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Ligand-Pharmaceuticals&v=1772647261083 "Chart of the company's future (projected) P/E Ligand Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma other
Ligand Pharmaceuticals owns a drug development platform and a portfolio of technologies that it licenses to other pharmaceutical companies. Its business model is based on royalties from sales of drugs developed using its technologies. This chart provides an overview of how the market values its diversified portfolio of future cash flows.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772647261140 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Ligand Pharmaceuticals owns a portfolio of technologies that it licenses to other pharmaceutical companies for drug development. Its business model is based on royalties from the sales of successful drugs. This is a diversified approach to biotech investment that is less risky than developing its own drugs from scratch.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772647261204 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Ligand Pharmaceuticals
Ligand Pharmaceuticals owns a drug development platform that it licenses to other pharmaceutical companies in exchange for royalties. Its business model is to generate revenue from the success of drugs developed by its partners. This graph shows how its technologies help create new drugs, which translates into a stream of royalties and payments for Ligand.
Profit of companies in the market segment - Pharma other
Ligand Pharmaceuticals operates on a royalty-based business model. The company owns platform technologies that it licenses to other pharmaceutical companies for drug development. This chart illustrates how the pharmaceutical industry can generate profits with reduced risk by receiving a percentage of sales from multiple drugs developed by its partners.
Overall market profit
Ligand Pharmaceuticals owns a portfolio of technologies that it licenses to other pharmaceutical companies, receiving royalties. Its revenue depends on the success of its partners' products. This graph, reflecting market conditions, influences funding for the entire pharmaceutical industry and, consequently, the activities of its partners.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Ligand Pharmaceuticals
Ligand Pharmaceuticals operates under a unique business model: it doesn't sell drugs, but rather owns a portfolio of technologies that it licenses to other pharmaceutical companies for drug development. Its revenue comes from royalties and licensing fees. This chart shows how analysts estimate the future cash flows from its technology platforms.
%20profit%20of%20the%20company%20Ligand%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Ligand-Pharmaceuticals&v=1772647261321 "Graph of future (projected) profit of the company Ligand Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma other
Ligand Pharmaceuticals has a unique business model: the company doesn't sell drugs, but rather owns technologies and patents that it licenses to other pharmaceutical companies, receiving royalties from their sales. This chart shows profitability projections for the pharmaceutical sector, allowing one to assess the success of Ligand's strategy of building a diversified royalty portfolio.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772647261337 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Ligand Pharmaceuticals operates under a unique business model, owning a drug development platform that it licenses to other pharmaceutical companies. Its revenue comes from royalties on the sales of its partners' successful drugs. Ligand's success depends on the clinical trial results of its partners, not on general economic trends.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772647261373 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Ligand Pharmaceuticals
Ligand Pharmaceuticals has a business model based on royalties from its drug development platform. This chart shows how the market values its royalty revenue. This value reflects the success of drugs developed by its partners using its technology and the diversification of its portfolio.
P/S market segment - Pharma other
Ligand Pharmaceuticals is a biopharmaceutical company with a portfolio of technologies that enable other companies to discover and develop drugs. This chart shows the average revenue estimate in the biotech sector. It helps understand how investors view Ligand's business model, which relies on royalties and licensing fees from its partners' successes.
P/S of the market as a whole
Ligand Pharmaceuticals owns a drug development platform and licenses its technologies to other pharmaceutical companies, receiving royalties on the sales of future drugs. Their business model is a diversified portfolio of bets on the success of other companies' drugs. This chart helps understand how the market values this unique, less risky model in the biotech sector.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Ligand Pharmaceuticals
Ligand Pharmaceuticals has a unique business model: it doesn't sell drugs, but rather owns technology platforms that it licenses to other pharmaceutical companies, receiving royalties on their future sales. Its estimated future revenue, shown in the graph, depends on the success of drugs developed by its partners using its technology.
%20P%2FS%20Ligand%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Ligand-Pharmaceuticals&v=1772647261437 "The graph of the company's future (projected) P/S Ligand Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma other
Ligand Pharmaceuticals has a unique business model: it develops technologies that help other pharmaceutical companies create drugs, earning royalties and licensing fees for doing so. This chart compares how investors value its royalty-based platform compared to more traditional biotech companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772647261474 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
Ligand Pharmaceuticals owns a drug development platform and licenses its technologies to other pharmaceutical companies, receiving royalties. This graph, reflecting overall R&D activity, is important for Ligand. Market optimism encourages pharmaceutical companies to invest more in the development of new drugs, which increases the likelihood of Ligand's technologies being used and, consequently, its future revenues.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772647261496 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Ligand Pharmaceuticals
Ligand Pharmaceuticals operates on a royalty-based business model. The company owns or manages a portfolio of technologies that it licenses to other pharmaceutical companies for drug development. This chart shows revenue, consisting of licensing fees and royalties from sales of drugs developed using its technologies.
Sales of companies in the market segment - Pharma other
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that focuses not on developing its own drugs, but on creating and acquiring royalty-generating technologies. Its Captisol platform is used in many drugs. The business is segmented by royalty source. This chart shows revenue from one of its key technology assets or partnerships.
Overall market sales
Ligand Pharmaceuticals is a biotech company with a unique business model. It owns platform technologies that it licenses to other pharmaceutical companies, receiving royalties from the sales of the final products. Its diversified royalty portfolio makes it less dependent on the success of a single drug and reflects the overall innovative activity of the pharmaceutical industry.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Ligand Pharmaceuticals
Ligand Pharmaceuticals operates on a royalty-based business model, owning patents for technologies used by other pharmaceutical companies to develop drugs. Its revenue forecast depends on the sales success of its partners' drugs. This is a diversified bet on the success of the entire pharmaceutical industry.
%20sales%20of%20the%20company%20Ligand%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Ligand-Pharmaceuticals&v=1772647261702 "Schedule of future (projected) sales of the company Ligand Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma other
Ligand Pharmaceuticals is a biopharmaceutical company with a portfolio of technologies that help other companies discover and develop drugs. This chart shows expectations for the entire biotech sector. It reflects analysts' views on R&D funding levels and drug development activity across the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772647261716 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Ligand Pharmaceuticals owns a drug development platform that it licenses to other pharmaceutical companies. Its revenues (royalties) depend on the sales success of these drugs. This graph of overall sales forecasts reflects the state of the economy, which impacts healthcare budgets and, consequently, the sales of its partner drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772647261774 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Ligand Pharmaceuticals
Ligand Pharmaceuticals is a biopharmaceutical company with a unique business model. It owns technology platforms that it licenses to other companies for drug development, receiving royalties and milestone payments. This chart illustrates how this low-cost R&D model allows it to generate a high profit margin on revenue.
Market segment marginality - Pharma other
Ligand Pharmaceuticals has a unique business model. They don't sell drugs, but rather own a portfolio of technologies (such as Captisol), which they license to other pharmaceutical companies to improve their products. This royalty-based model has very low costs. This chart illustrates how profitable this strategy is in the pharmaceutical industry.
Market marginality as a whole
Ligand Pharmaceuticals is a biopharmaceutical company with a unique business model based on developing or acquiring technologies that are then licensed to other companies. Its revenue comes from royalties and licensing fees. This chart shows overall profitability, but for LGND, success depends on the scientific breakthroughs of its partners using its technologies.
Employees in the company, segment and market as a whole
Number of employees in the company Ligand Pharmaceuticals
Ligand Pharmaceuticals operates on a business model based on royalties from the technologies it provides to other pharmaceutical companies. This chart shows its compact scientific and management team. A small staff is key to the high profitability of its model, which focuses on R&D and partnerships.
Share of the company's employees Ligand Pharmaceuticals within the market segment - Pharma other
Ligand Pharmaceuticals doesn't develop drugs itself, but rather owns technology platforms that it licenses to other pharmaceutical companies. Its small but highly effective team of scientists supports dozens of partnership programs. This chart illustrates its unique, intelligence-driven model as a biopharma employer.
Number of employees in the market segment - Pharma other
Ligand Pharmaceuticals operates on a business model based on licensing and royalties from its technology platforms, which are used by other pharmaceutical companies for drug development. This chart reflects employment in the pharmaceutical industry. The growing number of researchers in the industry creates more opportunities to apply Ligand's technologies and generate a stable royalty stream.
Number of employees in the market as a whole
Ligand Pharmaceuticals owns a drug development platform that it licenses to other pharmaceutical companies. Their success depends on their R&D activity. A strong economy, reflected in this chart, supports high levels of investment in biotechnology, leading to more partnerships and licensing deals for Ligand.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Ligand Pharmaceuticals (LGND)
Ligand Pharmaceuticals owns a drug discovery platform that it licenses to other pharmaceutical companies. Its business model is based on royalties and intellectual property. The astronomically high capitalization per employee, visible in this chart, is the core of its strategy. A small team of scientists manages a technology portfolio worth billions.
%20of%20the%20company%20Ligand%20Pharmaceuticals%20(LGND)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Ligand-Pharmaceuticals-LGND&v=1772647261967 "Chart of market capitalization per employee (in thousands of dollars) of the company Ligand Pharmaceuticals (LGND)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Ligand (LGND) isn't a traditional pharma company, but an "IP company." It doesn't sell drugs, but rather owns technology platforms (like Captisol), which it licenses to other companies for royalties. This is an "asset-light" model. This chart should show an extremely high market capitalization per employee.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772647262041 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Ligand Pharmaceuticals is a biotech company with a unique business model: it owns platform technologies that it licenses to other pharmaceutical companies for drug development. Their value lies in their intellectual property. The chart illustrates how a small team can generate significant value through royalties and partnerships.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772647262080 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Ligand Pharmaceuticals (LGND)
Ligand Pharmaceuticals (LGND) has a unique business model: rather than developing drugs themselves, they provide their patented technologies (such as Captisol) to other pharmaceutical companies. Their profit comes from royalties. This chart demonstrates the exceptional efficiency of this model. A small team of scientists and managers can generate significant profits by capitalizing on the successes of dozens of partners.
%20Chart%20Ligand%20Pharmaceuticals%20(LGND)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Ligand-Pharmaceuticals-LGND&v=1772647262116 "Company Profit Per Employee (in thousands of dollars) Chart Ligand Pharmaceuticals (LGND)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Ligand (LGND) isn't a traditional pharma company. It's an R&D platform business. They own technologies (like Captisol), which they license to other biotechs to create drugs, earning royalties. This chart shows the benchmark for "Pharma." The benchmark here (for "IP" companies) is *extremely* high. A tiny staff of scientists generates passive, high-margin income from patents.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772647262135 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Ligand Pharmaceuticals (LGND) is a biotech company with a royalty-based business model. They own technology platforms (such as Captisol), which they license to other pharmaceutical companies for drug development. This graph of average market profitability per employee helps us understand how effective this R&D model, which requires a small staff of scientists, is in generating profits.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772647262155 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Ligand Pharmaceuticals (LGND)
Ligand Pharmaceuticals operates on a business model based on royalties from technologies and drugs developed using its platform. This chart demonstrates the high profitability of this model. High revenue per employee is achieved through passive income generated from the success of its numerous partners.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Ligand-Pharmaceuticals-LGND&v=1772647262160 "Sales chart per company employee Ligand Pharmaceuticals (LGND)")
Sales per employee in the market segment - Pharma other
Ligand Pharmaceuticals uses a unique business model: instead of bringing their own drugs to market, they license their technologies (like Captisol) to other pharmaceutical companies and receive royalties. This graph shows revenue per employee. Ligand should have a high revenue per employee, as their staff is small and their income depends on the success of their partners. Comparison with the industry will demonstrate the effectiveness of their model.
Sales per employee for the market as a whole
Ligand Pharmaceuticals (LGND) has a unique business model. They don't sell drugs, but rather own technology platforms (for example, Captisol, which improves drug solubility), which they license to other pharmaceutical companies. Their revenue comes from royalties and fees. This is a highly efficient, asset-light model. This graph should indicate very high revenue per employee.
Short shares by company, segment and market as a whole
Shares shorted by company Ligand Pharmaceuticals (LGND)
Ligand Pharmaceuticals isn't a typical pharma. They don't sell drugs, but rather own technology platforms (like Captisol), which they license to other companies to develop their own drugs. Their business depends on the success of their partners. This chart shows the percentage of skeptics who fear that Ligand's partners will have problems in clinical trials or that their patents will expire.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Ligand-Pharmaceuticals-LGND&v=1772647262355 "Short Shares Chart for the Company Ligand Pharmaceuticals (LGND)")
Shares shorted by market segment - Pharma other
Ligand Pharmaceuticals (LGND) is a biotech company with a unique model. They don't sell drugs, but rather own technology platforms (such as Captisol), which they license to other pharmaceutical companies to improve their products. This chart shows the betting against the "biotech platform" sector. It reflects concerns about patent expirations or the success of partner drugs.
Shares shorted by the overall market
Ligand (LGND) is a biotech with a royalty-based model. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and shed their "risk." Although LGND's royalty-based model is safer than R&D, this pessimism threatens their partners, who could lose funding.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Ligand Pharmaceuticals (LGND)
Ligand Pharmaceuticals owns the Captisol platform used for drug development, receiving royalties. Its business depends on the success of its partners. This LGND chart, above 70, may reflect the success of Captisol-based drugs or new partnerships. Below 30, it reflects concerns about competition or partner failures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Ligand-Pharmaceuticals-LGND&v=1772647262392 "RSI 14 indicator chart for the company's stock Ligand Pharmaceuticals (LGND)")
RSI 14 Market Segment - Pharma other
Ligand Pharmaceuticals owns technology platforms (like OmniAb) for the discovery and development of new drugs. They receive royalties and licensing fees from partners who bring these drugs to market. This metric measures the overall momentum of the biotech platform sector and helps assess whether the entire segment is overheated by expectations.
RSI 14 for the overall market
Ligand Pharmaceuticals owns a drug development platform, receiving royalties from its partners. This chart shows the "health" of the biotech sector. During periods of euphoria, its partners (biotech companies) easily attract capital and advance research, promising future royalties for Ligand. During moments of panic, their funding dries up, and projects are shelved.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LGND (Ligand Pharmaceuticals)
Ligand Pharmaceuticals operates on a royalty-based business model. They own technology platforms (such as Captisol), which they license to other pharmaceutical companies for drug development. This chart shows the average analyst forecast. Their valuation depends on the success of their partner drugs and Ligand's ability to secure new deals.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LGND-Ligand-Pharmaceuticals&v=1772647262452 "A chart showing analyst consensus forecasts for the expected stock price. LGND (Ligand Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price LGND (Ligand Pharmaceuticals)
Ligand is a biotech royalty company. It doesn't sell drugs, but rather owns technology platforms (Captisol), which it licenses to other pharmaceutical companies in exchange for royalties. This chart shows the difference between the consensus estimate and the price, reflecting analysts' confidence in this asset-light business model.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LGND-Ligand-Pharmaceuticals&v=1772647262499 "A chart showing the difference between the consensus forecast and the actual stock price. LGND (Ligand Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Ligand Pharmaceuticals is a "biotech incubator." The company doesn't sell drugs, but rather owns a portfolio of patented technologies that it licenses to other pharmaceutical companies (receiving royalties). This chart shows analysts' general expectations for the entire pharmaceutical sector. It reflects whether experts believe in this royalty-based model.
Analysts' consensus forecast for the overall market share price
Ligand Pharmaceuticals is a company with a unique business model. They don't sell drugs, but rather own technology platforms (such as Captisol), which they license to other pharmaceutical companies to improve their products. This chart shows general market sentiment. For Ligand, which receives royalties, it's important to understand how these expectations influence the R&D activity and success of their partners. (346)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Ligand Pharmaceuticals
Ligand Pharmaceuticals (LGND) is a biotech company with an asset-light model. They don't bring drugs to market themselves, but rather own technology platforms (Captisol), which they license to other pharmaceutical companies to improve their drugs. This chart represents their royalty portfolio. Its dynamics reflect the success of dozens of partner drugs (such as Amgen's Kyprolis) that utilize their technology.
AKIMA Market Segment Index - Pharma other
Ligand is a biotech platform; the company doesn't sell drugs, but owns technologies (like Halozyme) that improve other drugs (for example, Captisol, which helps dissolve drugs). It earns money through royalties. This aggregate metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does Ligand's asset-light (royalty-based) model differentiate it from the average pharma company?
The AKIM Index for the overall market
Ligand is a biotech platform. The company doesn't sell drugs, but rather owns technologies (Captisol) that improve the giants' drugs and receive royalties. This chart, reflecting the market average, is just a backdrop. It helps us assess how this patent history, fueled by royalties, compares to general macroeconomic fluctuations.
